Extended Data Fig. 3: Change from baseline in cT1 relaxation time across time for TERN-501 monotherapy groups (Efficacy Analysis Set). | Nature Medicine

Extended Data Fig. 3: Change from baseline in cT1 relaxation time across time for TERN-501 monotherapy groups (Efficacy Analysis Set).

From: TERN-501 monotherapy and combination therapy with TERN-101 in metabolic dysfunction-associated steatohepatitis: the randomized phase 2a DUET trial

Extended Data Fig. 3

***P < 0.001 for TERN-501 monotherapy versus placebo. Error bars represent standard error. Week 6: placebo (n = 21); TERN-501 1 mg (n = 22) P = 0.1629; TERN-501 3 mg (n = 22) P = 0.2305; TERN-501 6 mg (n = 20) P = 0.0010. Week 12: placebo (n = 21); TERN-501 1 mg (n = 22) P = 0.1289; TERN-501 3 mg (n = 19) P = 0.1790; TERN-501 6 mg (n = 18) P = 0.0008. Statistical analysis was performed using a type III sum of squares ANCOVA model with treatment group as a fixed effect and baseline value as the covariate; comparison between groups was conducted at the 2-sided, 0.05 level of significance, and no adjustments for multiplicity were made. cT1, corrected T1; LS, least squares.

Source data

Back to article page